Clinical Trials Logo

Filter by:
NCT ID: NCT05816148 Active, not recruiting - Disabled Persons Clinical Trials

Leisure Physical Activity and Barriers to Physical Activity

Start date: April 20, 2023
Phase:
Study type: Observational

People with disabilities are less physically active than the general population. Currently, the level of leisure physical activity of people who are members or users of APF France handicap and their barriers to physical activity are unknown. The APF France handicap association is a national movement for the defense and representation of people with disabilities and their families. It represents all types and severities of disability. The objective of this study is to describe the level of leisure physical activity of people who are members or users of APF France handicap and their barriers to physical activity.

NCT ID: NCT05809531 Active, not recruiting - C3 Glomerulopathy Clinical Trials

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

VALE
Start date: May 29, 2023
Phase: Phase 3
Study type: Interventional

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

NCT ID: NCT05801692 Active, not recruiting - Clinical trials for Weaning of Mechanical Ventilation

Arterial Blood Gases in Weaning of Mechanical VEntilation

WAVE
Start date: December 21, 2022
Phase:
Study type: Observational

Weaning of mechanical ventilation is an important phase of ICU (Intensive Care Unit) patient hospitalization. Patients have to pass a spontaneous breathing trial, can have a phase of pause with mechanical ventilation before extubation and then can be weaned of invasive mechanical ventilation. Spontaneous breathing trial can be performed with a T-Tube or with Pressure support without PEEP (End Expiratory Positive Pressure) . Duration of spontaneous breathing trial range from 30 minutes to 120 minutes. Some clinicians performed an arterial blood gases at the end of the spontaneous breathing trial but this practice is not really defined and clearly explained in recommendations. Patients can benefit of ventilation support after extubation like non invasive pressure support or high flow nasal canulae. The procedure can be very different from a center to another, especially for arterial blood gases at the end of spontaneous breathing trial. Our aim is to observe in a multicenter study the daily practice of weaning of mechanical ventilation especially for arterial blood gases.

NCT ID: NCT05800535 Active, not recruiting - Cancer Clinical Trials

JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients

JUMP
Start date: March 1, 2023
Phase:
Study type: Observational

Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital). JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers. This study is non-interventional, it uses research on data that is already collected as part of conventional care, during the JUMP evaluation day. This study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received. Our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the JUMP program.

NCT ID: NCT05790824 Active, not recruiting - Knee Osteoarthritis Clinical Trials

Benefits of Spa Therapy in Saint-Lary Soulan for Knee Osteoarthritis

LARYTHERM
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The hypothesis is that the use of spa therapy in Saint-Lary Soulan for knee osteoarthritis treatment would have a therapeutic effect on this pathology. The main objective of this external comparison study is to evaluate the comparative effectiveness at 6 months of spa therapy in the Saint-Lary Soulan spa center on functional disability and pain (MCII: Minimal Clinical Important Improvement) in knee osteoarthritis compared to the control group of the Thermarthrose multicenter randomized clinical trial, receiving standard cares. The patients included in the Larytherm cohort will undergo a three-week spa therapy in Saint-Lary Soulan with a follow-up of 6 months after the end of spa therapy.

NCT ID: NCT05789355 Active, not recruiting - Sickle Cell Disease Clinical Trials

Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This is a pilot study of daily dosing of NUV001 as a dietary supplement in 12 sickle cell disease patients with 3 months of follow-up plus 1 month after supplementation.The present study is designed to evaluate, first, the safety and tolerability parameters as well as to measure the plasma and urinary residues of daily oral doses of NUV001. Secondly, the study will evaluate the impact of NUV001 on biological parameters and quality of life of patients.

NCT ID: NCT05785611 Active, not recruiting - Clinical trials for Axial Spondyloarthritis

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

OLINGUITO
Start date: April 5, 2023
Phase: Phase 3
Study type: Interventional

This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) and is safe to use. The study will also be comparing 200 mg with 100 mg filgotinib a day to see if the lower dose also helps to treat axSpA.

NCT ID: NCT05782075 Active, not recruiting - Heart Failure Clinical Trials

Biological Monitoring by a Nurse for Heart Failure Patients.

IC-SPEC
Start date: February 23, 2023
Phase:
Study type: Observational

The aim of this study is to evaluate the feasibility and safety of delegating remote biological monitoring in post-hospitalization for cardiac decompensation by a heart failure nurse.

NCT ID: NCT05780242 Active, not recruiting - COVID-19 Clinical Trials

Recrudescence of Eating Conduct Disorders and Covid-19

TCA-Covid19
Start date: July 12, 2022
Phase:
Study type: Observational

This qualitative study, combining psychiatric and anthropological perspectives, focused on the development and/or worsening of patients' eating disorders since Covid-19, as well as the experiences and perceptions of those around them - such as their family, teachers or staff. School and nursing staff. This multi-site approach will provide a multidimensional perspective on the experience of individuals and those around them, as well as a triangulation of data. The hypotheses to explain the increase in Eating Disorders (EDs) will be addressed through semi-structured interviews offered to study participants.

NCT ID: NCT05778071 Active, not recruiting - Clinical trials for Endocrine System Diseases

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

CALYPSO
Start date: June 7, 2023
Phase: Phase 3
Study type: Interventional

This study is investigating the safety and efficacy of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (cHP). During the first 24 weeks of the trial, participants will be randomized to receive eneboparatide or placebo. Study treatment is blinded: patients and doctors will not know which group each patient has been randomized to. All patients will start with a fixed dose of study treatment (eneboparatide or placebo), administered subcutaneously with a pre-filled pen. Study treatment will be individually titrated. After completion of the first 24 weeks, patients will be treated in the open label extension part of the study for 28 weeks. During this phase, all patients (including patients that were in the placebo group) will receive eneboparatide.